Invesco Ltd. Purchases 1,961,051 Shares of Kenvue Inc. (NYSE:KVUE)

Invesco Ltd. boosted its position in Kenvue Inc. (NYSE:KVUE) by 13.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 16,986,272 shares of the company’s stock after acquiring an additional 1,961,051 shares during the period. Invesco Ltd. owned 0.89% of Kenvue worth $362,657,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Cerity Partners LLC lifted its holdings in shares of Kenvue by 0.3% in the fourth quarter. Cerity Partners LLC now owns 793,970 shares of the company’s stock valued at $17,090,000 after purchasing an additional 2,529 shares in the last quarter. Federated Hermes Inc. lifted its holdings in shares of Kenvue by 11.6% in the fourth quarter. Federated Hermes Inc. now owns 8,420,638 shares of the company’s stock valued at $179,781,000 after purchasing an additional 876,624 shares in the last quarter. Waterloo Capital L.P. bought a new position in shares of Kenvue in the fourth quarter valued at approximately $288,000. Envestnet Asset Management Inc. lifted its holdings in shares of Kenvue by 79.4% in the fourth quarter. Envestnet Asset Management Inc. now owns 10,224,056 shares of the company’s stock valued at $218,284,000 after purchasing an additional 4,523,918 shares in the last quarter. Finally, Aviva PLC lifted its holdings in shares of Kenvue by 1,159.8% in the fourth quarter. Aviva PLC now owns 1,154,701 shares of the company’s stock valued at $24,653,000 after purchasing an additional 1,063,043 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Kenvue Trading Up 1.4 %

Shares of NYSE KVUE opened at $21.79 on Thursday. The business’s 50 day moving average is $22.61 and its two-hundred day moving average is $22.42. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $24.46. The stock has a market capitalization of $41.65 billion, a P/E ratio of 41.11, a PEG ratio of 2.62 and a beta of 1.02.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, research analysts expect that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th were given a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.76%. The ex-dividend date was Wednesday, February 12th. Kenvue’s payout ratio is presently 154.72%.

Analyst Ratings Changes

KVUE has been the topic of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft lowered Kenvue from a “buy” rating to a “hold” rating and dropped their price target for the stock from $25.00 to $24.00 in a report on Thursday, December 12th. Piper Sandler lifted their price target on Kenvue from $24.00 to $27.00 and gave the stock an “overweight” rating in a report on Monday, February 24th. Barclays lifted their price target on Kenvue from $21.00 to $23.00 and gave the stock an “equal weight” rating in a report on Thursday, March 27th. Royal Bank of Canada reiterated a “sector perform” rating and set a $24.00 price target on shares of Kenvue in a report on Monday, February 3rd. Finally, Citigroup decreased their target price on Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a research report on Wednesday, January 15th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $24.00.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.